Skip to content

Evaluation of Prognostic Potentials of Gingival Crevicular Fluid E-cadherin and Total Antioxidant Capacity

Prognostic Potentials of E-cadherin and Total Antioxidant Capacity in Gingival Crevicular Fluid of Moderately Deep Periodontal Pockets Treated With Nonsurgical Periodontal Therapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05994885
Enrollment
20
Registered
2023-08-16
Start date
2023-02-15
Completion date
2023-12-25
Last updated
2023-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis

Brief summary

Ability to anticipate the outcomes of periodontal therapy at baseline visit is crucial to outline and customize a treatment plan with predictable outcomes and cost-effectiveness. Presence of diverse range of health/disease-associated molecules in oral environment that reflect health and disease, together with clinical parameters, is an appealing approach to use them as biomarkers to diagnose, predict, and monitor periodontal disease. Among these proteins are E-cad and TAC which available evidence indicate that their concentrations in oral biofluids increase remarkably during periodontitis as compared to healthy periodontium.

Detailed description

Loss of attachment and formation of periodontal pockets are hallmarks of periodontitis. The treatment approach is either by nonsurgical or surgical periodontal therapy or a combination of both depending on the severity of the case. In general, sites with moderately deep pockets (4 to 6 mm) are responding favorably to nonsurgical periodontal therapy (NSPT). Nevertheless, some sites exhibit persistent pockets even with multiple treatment sessions which could be attributed to the presence of tissue invaders or aberrant immune response that impede healing process. Prediction of treatment outcomes based on clinical data is limited and sometimes lacking accuracy. Use of biomarkers that can be non-invasively collected from oral fluids e.g., gingival crevicular fluid (GCF) as diagnostic/predictive tools has gained attention in the last decade. For instance, E-Cadherin (E-cad) and total antioxidant capacity (TAC) are associated with periodontitis. E-cad is a transmembrane glycoprotein that is a key mediator of stable cell-cell adhesion of epithelial cells. E-cadherin-based adherens junctions specialized cell structures that mediate cell-cell adhesion and regulate cytoskeleton reorganization forming a continuous, linear circumferential belt (zonula adherens) around the apical part of the cell. While TAC, defined as the moles of oxidants neutralized by one liter of solution, is a biomarker measuring the antioxidant potential of body fluids. Available evidence indicates that the concentration of both molecules are substantially increased with increasing severity of periodontitis and vice versa in periodontal health. This suggests the potential of GCF-E-cad and TAC to predict the prognosis following NSPT.

Interventions

the included patients will undergo full-mouth supra- and subgingival debridement by using ultrasonic device and manual instrumentation at baseline. This is followed, after 1 week, by performing root surface debridement for all pockets with PPD = 4-6 mm for each patient. All patients will be instructed to brush their teeth twice daily and will be supplied with the same type of tooth paste and toothbrush, with suitable interdental aids.

Sponsors

Ali A Abdulkareem
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Masking description

The care provider is not aware about clinical parameters and biochemical analysis of GCF (E-cadherin and total antioxidant capacity).

Intervention model description

Patients with periodontitis, of any stage, having periodontal pockets of a moderate depth (4 to 6 mm) treated with nonsurgical periodontal therapy.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Systemically healthy adult patients (\> 18 years). * Periodontitis (interdental clinical attachment loss (CAL) detectable at ≥2 non-adjacent teeth, or buccal/oral CAL of ≥3mm with pocketing of \>3mm is detectable at ≥2 teeth). All patients should exhibit generalized periodontitis with pockets of PPD = 4 to 6 mm of any stage, unstable, and grade A to C. Only maxillary teeth with single root will be included.

Exclusion criteria

* Consumption of antibiotics or periodontal treatment 3-months prior to the study. * Pregnancy and lactation. * Smoker. * History of systemic disease e.g., diabetes mellitus. * Patients currently recruited in other trials. * Patients not willing to consent. * Periodontal pockets ≥ 7mm, active caries, endodontic problem. * Multi-rooted teeth will be also considered as exclusion reasons.

Design outcomes

Primary

MeasureTime frameDescription
Probing pocket depthBaseline, 1 week, then 1 month and 3 months after treatmentLinear distance, in mm, measured from the gingival margin to the base of periodontal pocket or sulcus.

Secondary

MeasureTime frameDescription
Clinical attachment lossBaseline, 1 week, then 1 month and 3 months after treatmentLinear distance, in mm, measured from the cementoenamel junction to the base of periodontal pocket or sulcus.
Bleeding on probingBaseline, 1 week, then 1 month and 3 months after treatmentPresence or absence of bleeding is detected after 30 seconds of inserting periodontal probe to the depth of periodontal pocket/sulcus
Gingival crevicular fluid E-cadherinBaseline, 1 month and 3 months after treatmentLevel of E-cadherin in GCF collected from periodontal pockets is determined by biochemical analysis
Total antioxidant capacityBaseline, 1 month and 3 months after treatmentLevel of TAC in GCF collected from periodontal pockets is determined by biochemical analysis

Countries

Iraq

Contacts

Primary ContactAli A Abdulkareem, PhD
ali.abbas@codental.uobaghdad.edu.iq07806866717

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026